Implications of the kynurenine pathway and quinolinic acid in Alzheimer's disease - PubMed (original) (raw)

Review

Implications of the kynurenine pathway and quinolinic acid in Alzheimer's disease

Gilles J Guillemin et al. Redox Rep. 2002.

Free article

Abstract

The kynurenine pathway (KP) is a major route of L-tryptophan catabolism leading to production of a number of biologically active molecules. Among them, the neurotoxin quinolinic acid (QUIN), is considered to be involved in the pathogenesis of a number of inflammatory neurological diseases. Alzheimer's disease is the major dementing disorder of the elderly that affects over 20 million peoples world-wide. Most of the approaches to explain the pathogenesis of Alzheimer's disease focus on the accumulation of amyloid beta peptide (A beta), in the form of insoluble deposits leading to formation of senile plaques, and on the formation of neurofibrillary tangles composed of hyperphosphorylated Tau protein. Accumulation of A beta is believed to be an early and critical step in the neuropathogenesis of Alzheimer's disease. There is now evidence for the KP being associated with Alzheimer's disease. Disturbances of the KP have already been described in Alzheimer's disease. Recently, we demonstrated that A beta 1-42, a cleavage product of amyloid precursor protein, induces production of QUIN, in neurotoxic concentrations, by macrophages and, more importantly, microglia. Senile plaques in Alzheimer's disease are associated with evidence of chronic local inflammation (especially activated microglia) A major aspect of QUIN toxicity is lipid peroxidation and markers of lipid peroxidation are found in Alzheimer's disease. Together, these data imply that QUIN may be one of the critical factors in the pathogenesis of neuronal damage in Alzheimer's disease. This review describes the multiple correlations between the KP and the neuropathogenesis of Alzheimer's disease and highlights more particularly the aspects of QUIN neurotoxicity, emphasizing its roles in lipid peroxidation and the amplification of the local inflammation.

PubMed Disclaimer

Cited by

Cooperation of non-effective concentration of glutamatergic system modulators and antioxidant against oxidative stress induced by quinolinic acid.
Dobrachinski F, Bastos LL, Bridi JC, Corte CL, de Ávila DS, da Rocha JB, Soares FA. Dobrachinski F, et al. Neurochem Res. 2012 Sep;37(9):1993-2003. doi: 10.1007/s11064-012-0820-3. Epub 2012 Jun 7. Neurochem Res. 2012. PMID: 22674085
Quinolinate promotes macrophage-induced immune tolerance in glioblastoma through the NMDAR/PPARγ signaling axis.
Kesarwani P, Kant S, Zhao Y, Prabhu A, Buelow KL, Miller CR, Chinnaiyan P. Kesarwani P, et al. Nat Commun. 2023 Mar 16;14(1):1459. doi: 10.1038/s41467-023-37170-z. Nat Commun. 2023. PMID: 36927729 Free PMC article.
Circulating Antibodies to IDO/THO Pathway Metabolites in Alzheimer's Disease.
Duleu S, Mangas A, Sevin F, Veyret B, Bessede A, Geffard M. Duleu S, et al. Int J Alzheimers Dis. 2010 Mar 15;2010:501541. doi: 10.4061/2010/501541. Int J Alzheimers Dis. 2010. PMID: 20721333 Free PMC article.
Structural Basis of Inhibitor Selectivity in Human Indoleamine 2,3-Dioxygenase 1 and Tryptophan Dioxygenase.
Pham KN, Lewis-Ballester A, Yeh SR. Pham KN, et al. J Am Chem Soc. 2019 Nov 27;141(47):18771-18779. doi: 10.1021/jacs.9b08871. Epub 2019 Nov 14. J Am Chem Soc. 2019. PMID: 31682426 Free PMC article.
Flipping the switches: CD40 and CD45 modulation of microglial activation states in HIV associated dementia (HAD).
Salemi J, Obregon DF, Cobb A, Reed S, Sadic E, Jin J, Fernandez F, Tan J, Giunta B. Salemi J, et al. Mol Neurodegener. 2011 Jan 11;6(1):3. doi: 10.1186/1750-1326-6-3. Mol Neurodegener. 2011. PMID: 21223591 Free PMC article.

Implications of the kynurenine pathway and quinolinic acid in Alzheimer's disease - PubMed (original) (raw)